Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 21, 2024

Tabelecleucel for Allogeneic HSCT or Solid Organ Transplant Recipients With EBV-Positive Posttransplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
Lancet Oncol 2024 Jan 31;[EPub Ahead of Print], KM Mahadeo, R Baiocchi, A Beitinjaneh, S Chaganti, S Choquet, D Dierickx, R Dinavahi, X Duan, L Gamelin, A Ghobadi, N Guzman-Becerra, M Joshi, A Mehta, WH Navarro, S Nikiforow, RJ O'Reilly, R Reshef, F Ruiz, T Spindler, S Prockop

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading